In Vitro Alternative Skin Sensitization Testing for Medical Devices: Methods, Standards, and Applica

In vitro alternative skin sensitization tests provide a scientifically validated, animal-free approach to evaluating the sensitizing potential of medical devices and their extracts, in line with OECD Test Guidelines 442C, 442D, and 442E and the ISO 10993 series of biocompatibility standards. These methods quantify the key mechanistic events of the skin sensitization adverse outcome pathway, including protein reactivity, keratinocyte activation, and dendritic cell activation. This article explains the principles, sample requirements, testing items, methods, and regulatory applications of in vitro sensitization alternatives for medical device biocompatibility assessment.

Technical Overview

Skin sensitization is a Type IV delayed hypersensitivity reaction in which low-molecular-weight leachables from a medical device covalently modify skin proteins, triggering an adaptive immune response that manifests as allergic contact dermatitis upon repeated exposure. ISO 10993-1 requires an evaluation of sensitization potential for any device or device component with patient-contacting surfaces, making it one of the core endpoints in biocompatibility testing programs for regulatory submissions worldwide.

Traditionally, sensitization was assessed in vivo using the Guinea Pig Maximization Test (GPMT) or the Buehler assay described in ISO 10993-10, and later the murine Local Lymph Node Assay (LLNA) specified in OECD Test Guideline 429 and endorsed by ISO 10993-10:2021. Driven by animal welfare legislation such as EU Directive 2010/63/EU and the global 3Rs principle (Replacement, Reduction, and Refinement), validated in chemico and in vitro alternative methods have been developed and formally incorporated into international standards and regulatory practice.

The in vitro strategy is anchored in the skin sensitization adverse outcome pathway (AOP), which describes four key events: (1) electrophilic binding of chemicals to skin proteins, (2) activation of keratinocytes, (3) activation of dendritic cells, and (4) proliferation of antigen-specific T cells. Complementary cell-based and chemistry-based assays address the first three key events:

• In chemico protein reactivity testing — OECD Test Guideline 442C (Direct Peptide Reactivity Assay, DPRA, and related variants such as the Amino acid Derivative Reactivity Assay, ADRA).
• Keratinocyte activation testing — OECD Test Guideline 442D (ARE-Nrf2 luciferase reporter gene assays, including KeratinoSens and LuSens).
• Dendritic cell activation testing — OECD Test Guideline 442E (h-CLAT, U-SENS, and IL-8 Luc assays).

Individual assay results are integrated under Integrated Approaches to Testing and Assessment (IATA) or formal Defined Approaches, such as the "2 out of 3" strategy documented in OECD Guideline 497. For medical devices specifically, ISO 10993-10 and the technical specification ISO/TS 11796 provide guidance on adapting these chemical-oriented methods to device extracts, and the results are interpreted within the risk management framework of ISO 10993-1, often supported by chemical characterization under ISO 10993-18 and toxicological risk assessment under ISO 10993-17.

Testing Samples

Medical Devices and Device Materials

Virtually any patient-contacting device or material can be evaluated, either as a finished device, a representative coupon, or a raw material sample. Typical submissions include:

• Surface-contacting devices: wound dressings, surgical drapes and gowns, examination and surgical gloves, adhesive tapes, electrodes, tubing, and catheters.
• External communication devices: infusion sets, syringes, cannulae, hemodialysis circuits, and endoscopic accessories.
• Implantable devices and components: orthopedic implants, dental materials, intraocular lenses, cardiovascular stents, and their constituent metals, polymers, ceramics, coatings, and adhesives.
• Materials under development: polymer formulations, masterbatch compounds, colorants, inks, curing agents, elastomers, and biodegradable resins.

Sample Preparation and Extraction

Test samples are prepared and extracted according to ISO 10993-12. Extraction is performed using both a polar solvent (typically physiological saline or water for injection) and a non-polar solvent (typically sesame oil) to capture leachables across a range of polarities. Standardized surface-area-to-volume ratios are applied, for example 3 cm²/mL or 6 cm²/mL depending on material thickness, or mass-based ratios such as 0.1–0.2 g/mL for porous or irregular materials. Extraction is conventionally performed at 37 °C ± 1 °C for 72 hours ± 2 hours, with accelerated or exaggerated conditions (e.g., 50 °C for 72 hours or 70 °C for 24 hours) permitted where justified to maximize leachable recovery.

Extract Handling and Vehicle Compatibility

Because device extracts frequently contain leachables at low concentrations, extracts may be concentrated by evaporation and reconstitution, or by solvent exchange, to improve assay sensitivity. Non-polar extracts obtained in sesame oil are typically exchanged into a cell-culture-compatible vehicle such as dimethyl sulfoxide (DMSO), with the final vehicle concentration in the culture system kept low (commonly ≤ 1%) to avoid cytotoxicity or assay interference. Osmolality, pH, turbidity, and chromatographic interference are evaluated during method suitability verification, as recommended in ISO/TS 11796.

Testing Items

In vitro sensitization studies address the following key measurement endpoints for each polar and non-polar extract:

• Overall sensitization hazard classification of the extract (sensitizer or non-sensitizer) based on the integrated results of the selected assays.
• Covalent protein reactivity, expressed as percent depletion of cysteine- and lysine-containing synthetic peptides (DPRA).
• Keratinocyte pathway activation, expressed as Nrf2-ARE-driven luciferase gene induction (fold induction) together with concurrent cell viability (KeratinoSens or LuSens).
• Dendritic cell activation, expressed as flow-cytometric relative fluorescence intensity of cell-surface markers CD86 and CD54 on THP-1 or U937 cells, together with cell viability (h-CLAT, U-SENS).
• Control items ensuring assay validity, including positive control chemicals (for example, 2,4-dinitrochlorobenzene), negative and solvent controls, and reference calibration standards.
• Supporting data such as extract cytotoxicity screening and, where applicable, chemical characterization of extractables and leachables under ISO 10993-18 for weight-of-evidence evaluation.

Testing Methods

Direct Peptide Reactivity Assay (DPRA)

The DPRA (OECD TG 442C) quantifies the ability of extract constituents to react with nucleophilic residues in skin proteins. Synthetic heptapeptides containing cysteine or lysine are incubated with the test extract or extract concentrate for approximately 24 hours at 25 °C, and the remaining parent peptide is quantified by high-performance liquid chromatography with UV detection. The mean percentage depletion of the cysteine and lysine peptides is calculated: mean depletion of 6.38% or less indicates no or minimal reactivity (negative prediction), while higher depletion values indicate limited, moderate, or high reactivity, supporting classification as a potential sensitizer. Method suitability must be demonstrated for complex extracts, as co-eluting leachables or excipients can interfere with chromatographic quantification.

ARE-Nrf2 Luciferase Keratinocyte Assays (KeratinoSens and LuSens)

These assays (OECD TG 442D) use immortalized human keratinocyte cell lines stably transfected with a luciferase reporter gene under the control of the antioxidant response element (ARE), which is upregulated by sensitizing electrophiles. Cells are exposed to serial dilutions of the extract for approximately 48 hours, after which luciferase activity and cell viability are measured. A result is considered positive when luciferase induction reaches at least 1.5-fold with statistical significance, is reproducible across independent runs, and occurs at concentrations where viability remains above 70%. The assay also generates an EC1.5 value, providing a quantitative indication of sensitizing potency within the assay domain.

Dendritic Cell Activation Assays (h-CLAT, U-SENS, and IL-8 Luc)

Dendritic cell assays (OECD TG 442E) model the third key event of the AOP. The h-CLAT assay uses human monocytic THP-1 cells exposed to serial dilutions of the extract for approximately 24 hours, followed by flow-cytometric measurement of the co-stimulatory markers CD86 and CD54. A positive prediction is assigned when CD86 expression increases by at least 150% or CD54 expression by at least 200% relative to the solvent control at concentrations where cell viability remains at or above 50%. The U-SENS assay applies a similar principle to U937 cells with CD86 as the sole marker, and the IL-8 Luc assay measures IL-8 promoter-driven luciferase induction, offering an additional mechanistically complementary readout.

Defined Approaches and Integrated Assessment

No single in vitro assay captures the entire sensitization AOP, so results are combined using Defined Approaches codified in OECD Guideline 497. The widely used "2 out of 3" strategy combines DPRA, an ARE-Nrf2 assay (KeratinoSens or LuSens), and h-CLAT: concordant results from at least two of the three assays support a hazard classification. For medical devices, this integrated verdict is interpreted alongside device use context, contact duration, extract chemistry, and in silico predictions from tools such as the OECD QSAR Toolbox, consistent with the ISO 10993-1 risk-based biological evaluation framework.

Quality Assurance and Compliance

Studies should be performed under a documented quality system, preferably Good Laboratory Practice (GLP) or within laboratories accredited to ISO/IEC 17025. Accredited third-party laboratories maintain validated test systems, verify method suitability for each matrix, run proficiency substances, and report raw data, acceptance criteria, and integration logic in a format suitable for regulatory review.

Applications

In vitro sensitization alternatives support the full product lifecycle of medical devices, from early research to post-market compliance:

• Regulatory biocompatibility submissions, including premarket notifications and approvals reviewed by authorities such as the U.S. FDA, notified bodies under the EU Medical Device Regulation (MDR) 2017/745, and agencies in China, Japan, and other jurisdictions that increasingly accept alternative methods within a weight-of-evidence justification.
• Research and development screening to compare candidate polymers, coatings, adhesives, colorants, and suppliers before committing resources to full device evaluation.
• Change control, including assessment of material substitutions, formulation changes, manufacturing process changes, and new sterilization methods.
• Animal reduction and welfare programs, enabling manufacturers to meet corporate 3Rs commitments and regional requirements to minimize vertebrate animal use.
• Weight-of-evidence toxicological risk assessment, where assay results are combined with chemical characterization and literature data to justify reduced or waived in vivo testing.
• Academic and industrial research into sensitization mechanisms, extractable toxicology, and new approach methodologies (NAMs).

FAQ

Below are answers to common questions regarding in vitro sensitization testing of medical devices.

Are in vitro sensitization tests accepted by regulators for medical device submissions?

Acceptance is growing steadily. OECD-validated methods are referenced in ISO 10993-10:2021, and ISO/TS 11796 provides device-specific guidance. Many submissions now rely on a battery of DPRA, ARE, and dendritic cell assays supported by chemical characterization; however, specific acceptance depends on the jurisdiction, device classification, and completeness of the risk-based justification, so early dialogue with accredited third-party laboratories and the relevant authority is recommended.

How do in vitro results compare with traditional guinea pig or LLNA tests?

The OECD-validated methods demonstrate sensitivity and specificity comparable to the LLNA for a broad range of test substances when used within Defined Approaches such as the "2 out of 3" strategy. Because device extracts are dilute and chemically complex, careful extract concentration, solvent exchange, and interference controls are essential to maintain equivalent predictive performance.

What samples and how many extractions are needed?

Testing typically requires sufficient material to prepare both polar (saline) and non-polar (sesame oil) extracts under ISO 10993-12 conditions, such as 37 °C for 72 hours. The required sample quantity depends on the device geometry and the chosen extraction ratio, and both extracts are generally evaluated across the full assay battery.

Which method should be selected: DPRA, KeratinoSens, or h-CLAT?

The methods target different key events of the sensitization AOP and are most powerful when combined. DPRA addresses molecular initiating reactivity, ARE assays address keratinocyte responses, and h-CLAT addresses dendritic cell activation; running all three enables the "2 out of 3" Defined Approach, which provides the strongest integrated hazard prediction.

How long does in vitro sensitization testing take?

A complete three-assay battery, including extraction, method suitability verification, and integrated reporting, is typically completed within two to four weeks, substantially faster than the multi-week dosing and observation phases required for in vivo studies.

What happens if in vitro results are positive or inconclusive?

A positive or discordant result does not automatically block a submission. It triggers a follow-up strategy that may include chemical characterization of the responsible leachables, read-across or QSAR analysis, toxicological risk assessment under ISO 10993-17, refinement of extract concentration, or, as a last resort, a confirmatory in vivo study justified under the 3Rs framework.